Treatment for Completers of the Study B7A-MC-MBCM

NCT00266695 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

203

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Retinopathy

Interventions

DRUG: Ruboxistaurin

Sponsor

Chromaderm, Inc.